Key result
NAFLD affects ~53% of hemodialysis patients and is linked to more carotid atherosclerosis and CVD events.
Why the study?
Non-alcoholic fatty liver disease (NAFLD) has been recognized as a new risk factor for adverse cardiovascular events in the general population, but its incidence and cardiovascular risk association in hemodialysis patients were unclear.
Is the presence of non-alcoholic fatty liver disease associated with a higher risk of adverse cardiovascular events and carotid atherosclerosis in hemodialysis patients?
Observational (n=122)
Is the presence of non-alcoholic fatty liver disease associated with a higher risk of adverse cardiovascular events and carotid atherosclerosis in hemodialysis patients?
NAFLD is highly prevalent in hemodialysis patients and is associated with advanced carotid atherosclerosis and increased adverse cardiovascular events, serving as a potential marker for elevated cardiovascular risk.
BACKGROUND/AIMS: Cardiovascular diseases (CVD) are the leading cause of mortality in hemodialysis (HD) patients. Recently, non-alcoholic fatty liver disease (NAFLD) has been recognized as a new risk factor for adverse CVD events in the general population. Our aim was to analyze the incidence of NAFLD in HD patients by using transient elastography and to analyze whether the presence of NAFLD is associated with a higher CVD risk in HD patients. METHODS: The subjects were 72 HD patients and 50 sex- and age-matched controls. RESULTS: NAFLD was found in 52.8% of HD patients. HD patients with NAFLD showed more carotid atherosclerosis and more adverse CVD events than HD patients without NAFLD and control subjects. CONCLUSION: We showed for the first time that HD patients have a high prevalence of NAFLD. HD patients with NAFLD show an advanced carotid atherosclerosis. Detection of NAFLD by transient elastography should alert to the existence of an increased cardiovascular risk in HD patients.
No takes yet. Share an insight, caveat, or question.
Mikolašević et al. (2014) conducted an observational in Hemodialysis (n=122). Non-alcoholic fatty liver disease (NAFLD) vs. Hemodialysis patients without NAFLD and control subjects was evaluated on Prevalence of NAFLD and incidence of adverse CVD events and carotid atherosclerosis. Non-alcoholic fatty liver disease was present in 52.8% of hemodialysis patients and was associated with more carotid atherosclerosis and adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: